Navigating insurance
Rosa's Humira costs $6,900. A near-identical drug costs $1,038.
How formulary tools miss alternatives, and why a broker helps.
Rosa takes Humira for rheumatoid arthritis. It costs $6,900 a month.
When she had group insurance, the PBM — the company that manages her plan’s drug benefits — negotiated a price. She paid a $75 copay. Now she’s shopping on the individual market and needs to check which plans cover her medication.
A single headline figure: Humira’s list price of $6,922 per month, before any plan discount or cost sharing.
$6,922 Humira list price per month
She searches her plan’s formulary — the list of drugs the plan covers.
She types “Humira.” Good news: it’s covered. Bad news: it’s on Tier 5 (specialty), with 40% coinsurance after a $2,000 drug deductible. Her annual out-of-pocket for Humira alone: over $5,000.
The single search result for Humira, showing it is covered on Tier 5 at 40% coinsurance after a $2,000 drug deductible, leaving Rosa over $5,000 a year out of pocket.
Search: “Humira” — 1 result
Finding Cheaper Drug Alternatives on Your
- Humira — brand biologic
- Covered
- Formulary tier
- Tier 5 (specialty)
- List price
- $6,922/mo
- Rosa pays
- 40% after $2,000 drug deductible
- Her year, for this drug alone
- Over $5,000
What Rosa doesn’t know: there are 10+ alternatives she never searched for.
Biosimilars — like Hadlima — are near-identical versions of Humira approved by the FDA. Hadlima is priced 85% below Humira’s list price. Some biosimilars are designated “interchangeable,” meaning a pharmacist can substitute them without a new prescription, just like a generic. But Rosa’s formulary tool didn’t suggest them. She’d have to know to search by name.
Four drugs in the same class compared by monthly list price: Humira at $6,922, Amjevita at $3,115, Hyrimoz at $1,315, and Hadlima at $1,038 — each bar drawn against a $7,000 scale.
Same drug class — very different prices
Brand biologic · Tier 5 · 40% coinsurance
Biosimilar · Tier 4 · 25% coinsurance
Biosimilar · Tier 3 · $75 copay
Biosimilar (interchangeable) · Tier 3 · $75 copay
Hadlima is 85% less than Humira — and FDA-designated interchangeable
This is where a broker or agent earns their fee.
A broker can pull the plan’s full formulary for Rosa’s drug class — TNF blockers, in this case — and identify which alternatives are covered and at what tier. Rosa takes that list to her rheumatologist, who makes the clinical decision. The broker surfaces options. The doctor decides what’s safe. Rosa saves thousands.
A three-stage sequence — the broker pulls the full formulary for the drug class, the rheumatologist decides what is clinically appropriate, and Rosa switches — alongside her annual out-of-pocket falling from over $5,000 to under $1,000.
-
Broker pulls the full formulary for TNF blockers
-
Rheumatologist decides what is clinically appropriate
-
Rosa switches to a covered alternative
Rosa’s year, out of pocket
- Staying on Humira
- Over $5,000
- After the switch
- Under $1,000
The formulary lookup tool showed Rosa one answer. The real answer was much bigger.
Most drug search tools operate at the wrong altitude — they confirm whether YOUR drug is covered, but don’t show you the landscape of alternatives in the same therapeutic class. For specialty medications, this blind spot can cost thousands of dollars a year.
A two-column comparison of what the formulary lookup tool returned against what the full drug class contained: one drug versus ten or more, a lowest list price of $6,922 versus $1,038, and an annual out-of-pocket of over $5,000 versus under $1,000.
| Measure | What the lookup tool showed | What the drug class held |
|---|---|---|
| Drugs surfaced | 1 | 10+ |
| Lowest list price | $6,922/mo | $1,038/mo |
| Lowest tier offered | Tier 5 | Tier 3 |
| Rosa’s year, out of pocket | Over $5,000 | Under $1,000 |